Kymera Therapeutics, Inc.
KYMR
Classificação em ações
#2179
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Preço da ação
$114.06
Valor de mercado
$9.38B
Variação (1 dia)
5.54%
Variação (1 ano)
88.52%
País
US
Negociar Kymera Therapeutics, Inc. (KYMR)
Categoria
Healthcare
Lucros da Kymera Therapeutics, Inc. (KYMR)
Lucros em Jun 2026 TTM: $-299.87M
De acordo com os últimos relatórios financeiros da Kymera Therapeutics, Inc., os ganhos atuais da empresa são de $-299.87M. Em 2023, a empresa teve ganhos de $-146.96M, um aumento em relação a aos ganhos de 2022, que foram de $-154.81M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Kymera Therapeutics, Inc. de 2018 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $-299.87M | 33.96% |
| 2024 | $-223.86M | 52.32% |
| 2023 | $-146.96M | -5.07% |
| 2022 | $-154.81M | 54.47% |
| 2021 | $-100.22M | 119.81% |
| 2020 | $-45.59M | 10.54% |
| 2019 | $-41.25M | 92.14% |
| 2018 | $-21.47M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| $5.27B | -1,859.04% |
US
|
|
| $-3.09B | 929.44% |
US
|
|
| $-4.02B | 1,239.30% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -750.49% |
NL
|
